5-溴-2-甲基-4(1H)-嘧啶酮 | 1676-57-9

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-溴-2-甲基-4(1H)-嘧啶酮
• 英文名称: 5-bromo-2-methyl-4(3H)-pyrimidinone
• 英文别名: 5-bromo-2-methylpyrimidin-4(3H)-one；5-bromo-2-methyl-3H-pyrimidin-4-one；5-Brom-2-methyl-3H-pyrimidin-4-on；5-Bromo-2-methylpyrimidin-4-OL；5-bromo-2-methyl-1H-pyrimidin-6-one
• CAS: 1676-57-9
• 化学式: C₅H₅BrN₂O
• 分子量: 189.011
• InChiKey: WXBZTJGZVILJIA-UHFFFAOYSA-N

物化性质

• 密度：
  1.84±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-4-hydroxy-2-methylpyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-4-hydroxy-2-methylpyrimidine
CAS number: 1676-57-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H5BrN2O
Molecular weight: 189.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-2-甲基-4(1H)-嘧啶酮 在 三氯氧磷 作用下， 反应 1.0h， 以98%的产率得到5-溴-4-氯-2-甲基嘧啶
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS
  [FR] DÉRIVÉS DE PYRIDONE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE PDE10

  摘要：

  本发明涉及取代吡啶酮化合物，其可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及利用这些化合物治疗神经学和精神疾病，如精神分裂症、精神病或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的疾病。

  公开号：

  WO2014081617A1
• 作为产物：
  描述：

  2-甲基-4-羟基嘧啶 在 氯仿 、 溴 作用下， 生成 5-溴-2-甲基-4(1H)-嘧啶酮
  参考文献：
  名称：

  Ochiai et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1943, vol. 63, p. 25,27

  摘要：

  DOI：

文献信息

• [EN] PYRIMIDINE PDE10 INHIBITORS<br/>[FR] INHIBITEURS PYRIMIDINES DE PDE10
  申请人：MERCK SHARP & DOHME

  公开号：WO2014081619A1

  公开（公告）日：2014-05-30

  The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及嘧啶化合物，这些化合物用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统障碍的治疗剂。本发明还涉及使用这些化合物来治疗神经和精神障碍，如精神分裂症、精神疾病或亨廷顿病，以及与纹状体功能减退或基底神经节功能障碍相关的疾病。
• Mono- and Dinuclear α-Diimine Nickel(II) and Palladium(II) Complexes in C–S Cross-Coupling
  作者：Md Muktadir Talukder、Justin T. Miller、John Michael O. Cue、Chinthaka M. Udamulle、Abhi Bhadran、Michael C. Biewer、Mihaela C. Stefan

  DOI：10.1021/acs.organomet.0c00732

  日期：2021.1.11

  significantly reduced by air and moisture sensitivity, as well as harsh reaction conditions. Herein, we report four highly air- and moisture-stable well-defined mononuclear and bridged dinuclear α-diimine Ni(II) and Pd(II) complexes for C–S cross-coupling. Various ligand frameworks, including acenaphthene- and iminopyridine-based ligands, were employed, and the resulting steric properties of the catalysts were

  空气和水分的敏感性以及苛刻的反应条件大大降低了过渡金属催化体系在CS交叉偶联反应中的作用。在此，我们报告了用于C–S交叉偶联的四种高度空气和水分稳定的定义明确的单核和桥接双核α-二亚胺Ni（II）和Pd（II）配合物。使用了各种配体构架，包括基于ph和亚氨基吡啶的配体，并评估了催化剂的最终空间性质，并将其与反应结果相关联。在有氧条件和低温下，与以前报道的催化剂相比，Ni和Pd体系均表现出更宽的底物范围和官能团耐受性。由含有烷基，苄基和杂芳基的硫醇合成了40多种化合物。也，从硫醇和卤化物源掺入药学上有活性的杂芳基部分。值得注意的是，通过在广泛的底物范围内提供几乎定量的产率，桥接的双核五坐标Ni络合物的性能优于其余三个单四坐标或六坐标Ni的络合物。
• [EN] SIGMA-1 RECEPTOR LIGANDS AND THERAPEUTIC USES THEREOF<br/>[FR] LIGANDS DU RÉCEPTEUR SIGMA-1 ET SES UTILISATIONS THÉRAPEUTIQUES
  申请人：UNIV STRASBOURG

  公开号：WO2021123174A1

  公开（公告）日：2021-06-24

  The present invention relates to the field of medicine. More specifically, the present invention relates to compounds that are sigma-1 receptor agonists and their use for the treatment of central nervous system disorders, including cognitive or neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, and multiple sclerosis.

  本发明涉及医学领域。更具体地说，本发明涉及σ-1受体激动剂化合物及其在治疗中枢神经系统疾病方面的用途，包括认知或神经退行性疾病，如阿尔茨海默病、帕金森病、亨廷顿病、肌萎缩侧索硬化症和多发性硬化症。
• [EN] PYRIMIDINONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE PYRIMIDINONE ET LEURS UTILISATIONS
  申请人：HUTCHISON MEDIPHARMA LTD

  公开号：WO2022037585A1

  公开（公告）日：2022-02-24

  It relates to pyrimidinone compounds and uses thereof. In particular, it relates to pyrimidinone compounds of formula (I), and the pharmaceutical compositions, the preparing methods and the uses thereof, wherein the variables are as defined in the description.

  本发明涉及嘧啶酮化合物及其用途。具体而言，本发明涉及公式（I）的嘧啶酮化合物，以及制备方法、制药组合物和用途，其中变量如描述中所定义。
• Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors
  申请人：Breslin Michael J.

  公开号：US08975261B2

  公开（公告）日：2015-03-10

  The present invention is directed to aryloxymethyl cyclopropane derivatives which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及芳基氧甲基环丙烷衍生物，其可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及使用这些化合物治疗神经和精神障碍，如精神分裂症、精神病或亨廷顿病，以及与纹状体功能不足或基底节功能障碍有关的疾病。

表征谱图